Case Review: Targets Are Met—Can You Stick the Landing?
David Rubin, MD
Jennifer Geremia, PA-C
Treat-to-Target: Are We There Yet?
Kimberly D. Orleck, PA-C
Switching Strategies: Switch or Stay—What’s Your Call?
Brooke Hodnick, PA-C, MPAS
Tailoring Treatment: Can You Select the Best Therapy?
When Topicals Fail: The New IPC Consensus Every Clinician Should Know
Linda Stein Gold, MD
Bruce Strober, MD, PhD
The Tumor That’s Not So Tiny: Understanding the Impact of TGCT
A.J. Gelderblom, MD, PhD
Beyond the Scalpel: When TGCT Surgery Isn’t the Solution
Michiel van de Sande, MD, PhD
Unlocking the CSF1R Code: Targeted Pathways and Tailored Choices
Applying the Evidence: TGCT Treatment Insights for Sports Medicine Physicians
Chelsea Cole, MD
The Safety Equation: Managing Adverse Events Associated With CSF1R Inhibitors in TGCT
Patient Perspective: Navigating TGCT Treatment—Surgery vs Systemic Therapy
Emerging Evidence in Focus: Interpreting Data on Next-Generation CSF1R TKIs
CDH6 in Focus: Advancing Biomarker-Driven Strategies for Platinum-Resistant Ovarian Cancer
Kathleen Moore, MD, MS
Joyce F. Liu, MD, MPH
MOA: CDH6-Targeted Antibody-Drug Conjugates
Clinical Evidence: Insights From Early Trials of CDH6-Targeted Therapies
Looking Ahead: Integrating CDH6-Targeted Therapies Into Ovarian Cancer Treatment Paradigms
Loading...
We're glad to see you're enjoying Prova Education… but how about a more personalized experience?
Press cancel to remain on Prova Education. Press the link below or the continue button to keep going.